{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:51:44Z","timestamp":1790599904516,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH R25-MH112473"],"award-info":[{"award-number":["NIH R25-MH112473"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00213-025-06907-7","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:57:09Z","timestamp":1761533829000},"page":"1593-1600","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Provider perspectives on challenges in treatment during psychedelic therapy"],"prefix":"10.1007","volume":"243","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9842-2110","authenticated-orcid":false,"given":"David A.","family":"Bender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep M.","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua S.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Hellerstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baris C.","family":"Ercal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Lenze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"issue":"1","key":"6907_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1176\/appi.ajp.20231063","volume":"182","author":"ST Aaronson","year":"2025","unstructured":"Aaronson ST et al (2025) Single-dose psilocybin for depression with severe treatment resistance: an open-label trial. Am J Psychiatry 182(1):104\u2013113","journal-title":"Am J Psychiatry"},{"key":"6907_CR2","doi-asserted-by":"crossref","unstructured":"Applebaum PS (2022) Psychedelic research and the real world. Available from: https:\/\/www.nature.com\/articles\/d41586-022-02875-6","DOI":"10.1038\/d41586-022-02875-6"},{"issue":"6","key":"6907_CR3","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1007\/s00213-021-06049-6","volume":"239","author":"D Bender","year":"2022","unstructured":"Bender D, Hellerstein DJ (2022) Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research. Psychopharmacology 239(6):1907\u20131932","journal-title":"Psychopharmacology"},{"key":"6907_CR4","doi-asserted-by":"publisher","unstructured":"Bender DA, Nayak SM, Siegel JS,Hellerstein DJ, Ercal BC, Lenze EJ (2025a) Psychological support approaches in psychedelic therapy:results from a survey of sychedelic practitioners. J Clin Psychiatry 86(1):24m15521. https:\/\/doi.org\/10.4088\/JCP.24m15521","DOI":"10.4088\/JCP.24m15521"},{"key":"6907_CR5","doi-asserted-by":"publisher","unstructured":"Bender DA, Nayak SM, Siegel JS, Hellerstein DJ, Ercal BC, Lenze EJ (2025b) The role of touch in psychedelic therapy: perspectives from a survey of practitioners in research settings. Am J Psychother. https:\/\/doi.org\/10.1176\/appi.psychotherapy.20240025","DOI":"10.1176\/appi.psychotherapy.20240025"},{"issue":"1","key":"6907_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1176\/appi.ajp.20230643","volume":"181","author":"MP Bogenschutz","year":"2024","unstructured":"Bogenschutz MP (2024) Pharmacological and nonpharmacological components of psychedelic treatments: the whole is not the sum of the parts. Am J Psychiatry 181(1):75","journal-title":"Am J Psychiatry"},{"issue":"2","key":"6907_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"2006","author":"VCV Braun","year":"2006","unstructured":"Braun VCV (2006) Using thematic analysis in psychology. Qual Res Psychol 2006(2):77\u2013101","journal-title":"Qual Res Psychol"},{"issue":"1","key":"6907_CR8","doi-asserted-by":"publisher","first-page":"15998","DOI":"10.1038\/s41598-023-41145-x","volume":"13","author":"R Bremler","year":"2023","unstructured":"Bremler R et al (2023) Case analysis of long-term negative psychological responses to psychedelics. Sci Rep 13(1):15998","journal-title":"Sci Rep"},{"issue":"12","key":"6907_CR9","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1177\/0269881116662634","volume":"30","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro TM et al (2016) Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol 30(12):1268\u20131278","journal-title":"J Psychopharmacol"},{"issue":"7","key":"6907_CR10","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0269881118754710","volume":"32","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL et al (2018) Psychedelics and the essential importance of context. J Psychopharmacol 32(7):725\u2013731","journal-title":"J Psychopharmacol"},{"issue":"10","key":"6907_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293349","volume":"18","author":"J Evans","year":"2023","unstructured":"Evans J (2023) Extended difficulties following the use of psychedelic drugs: a mixed methods study. PLoS ONE 18(10):e0293349","journal-title":"PLoS ONE"},{"key":"6907_CR12","unstructured":"FDA Guidance on Psychedelic Trials. Available from: https:\/\/www.fda.gov\/media\/169694\/download"},{"issue":"1","key":"6907_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1176\/appi.ajp.20241025","volume":"182","author":"GA Fonzo","year":"2025","unstructured":"Fonzo GA, Nemeroff CB, Kalin N (2025) Psychedelics in psychiatry: oh, what a trip! Am J Psychiatry 182(1):1\u20135","journal-title":"Am J Psychiatry"},{"issue":"12","key":"6907_CR14","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1177\/0269881116675757","volume":"30","author":"GM Goodwin","year":"2016","unstructured":"Goodwin GM (2016) Psilocybin: psychotherapy or drug? J Psychopharmacol 30(12):1201\u20131202","journal-title":"J Psychopharmacol"},{"issue":"18","key":"6907_CR15","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM et al (2022) Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med 387(18):1637\u20131648","journal-title":"N Engl J Med"},{"key":"6907_CR16","unstructured":"Goodwin GM, et al (2023) Must Psilocybin Always \"Assist Psychotherapy\"? Am J Psychiatry p appiajp20221043"},{"key":"6907_CR17","unstructured":"Grinspoon L and Bakalar JB (1979) Psychedelic drugs reconsidered. New York: Basic Books. xiv, p 343"},{"key":"6907_CR18","unstructured":"Grof S (1994) LSD psychotherapy. 2nd ed. 1994, Alameda, CA: Hunter House. p\u00a0352"},{"issue":"5","key":"6907_CR19","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1177\/1363461520983684","volume":"59","author":"N Gukasyan","year":"2022","unstructured":"Gukasyan N, Nayak SM (2022) Psychedelics, placebo effects, and set and setting: insights from common factors theory of psychotherapy. Transcult Psychiatry 59(5):652\u2013664","journal-title":"Transcult Psychiatry"},{"key":"6907_CR20","unstructured":"Hardman J (2024) MindMed\u2019s \u2018Total Elimination\u2019 of Psychotherapy in LSD Study Stokes Debate Around Its Role in Psychedelic Therapies. Available from: https:\/\/psychedelicalpha.com\/news\/mindmeds-total-elimination-of-psychotherapy-in-lsd-study-stokes-debate-around-its-role-in-psychedelic-therapies"},{"key":"6907_CR21","unstructured":"Hardman J (2024) Interview: Compass Pathways CEO Kabir Nath Discusses Commercialisation, \u2018Psychological Support\u2019 and Competitive Landscape. Available from: https:\/\/psychedelicalpha.com\/news\/interview-compass-pathways-ceo-kabir-nath-discusses-commercialisation-psychological-support-and-competitive-landscape"},{"issue":"2","key":"6907_CR22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA (2009) Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377\u2013381","journal-title":"J Biomed Inform"},{"key":"6907_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA et al (2019) The REDCap consortium: building an international community of software platform partners. J Biomed Inform 95:103208","journal-title":"J Biomed Inform"},{"issue":"12","key":"6907_CR24","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/0269881116677852","volume":"30","author":"I Hartogsohn","year":"2016","unstructured":"Hartogsohn I (2016) Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J Psychopharmacol 30(12):1259\u20131267","journal-title":"J Psychopharmacol"},{"issue":"12","key":"6907_CR25","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamapsychiatry.2024.2546","volume":"81","author":"JT Hinkle","year":"2024","unstructured":"Hinkle JT et al (2024) Adverse events in studies of classic psychedelics: a systematic review and meta-analysis. JAMA Psychiatr 81(12):1225\u20131235","journal-title":"JAMA Psychiatr"},{"issue":"1","key":"6907_CR26","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1176\/appi.ajp.20230884","volume":"182","author":"N Kirlic","year":"2025","unstructured":"Kirlic N et al (2025) Compass psychological support model for COMP360 psilocybin treatment of serious mental health conditions. Am J Psychiatry 182(1):126\u2013132","journal-title":"Am J Psychiatry"},{"issue":"3","key":"6907_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0300501","volume":"19","author":"AW Levin","year":"2024","unstructured":"Levin AW et al (2024) The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. PLoS ONE 19(3):e0300501","journal-title":"PLoS ONE"},{"key":"6907_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2025.116381","volume":"345","author":"F Muller","year":"2025","unstructured":"Muller F et al (2025) Suicide of a patient shortly after psilocybin-assisted psychedelic therapy: a case report. Psychiatry Res 345:116381","journal-title":"Psychiatry Res"},{"key":"6907_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.788155","volume":"12","author":"R Murphy","year":"2022","unstructured":"Murphy R (2022) Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression. Front Pharmacol 12:788155","journal-title":"Front Pharmacol"},{"key":"6907_CR30","doi-asserted-by":"crossref","unstructured":"Nayak SM et al (2023) Control Conditions in Randomized Trials of Psychedelics: An ACTTION Systematic Review. J Clin Psychiatry 84(3)","DOI":"10.4088\/JCP.22r14518"},{"issue":"2","key":"6907_CR31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE (2016) Psychedelics. Pharmacol Rev 68(2):264\u2013355","journal-title":"Pharmacol Rev"},{"issue":"1","key":"6907_CR32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1176\/appi.ajp.20230661","volume":"181","author":"KC O\u2019Donnell","year":"2024","unstructured":"O\u2019Donnell KC (2024) Misinterpretations and omissions: a critical response to Goodwin and colleagues\u2019 commentary on Psilocybin-assisted therapy. Am J Psychiatry 181(1):74\u201375","journal-title":"Am J Psychiatry"},{"issue":"1","key":"6907_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1176\/appi.ajp.20230785","volume":"182","author":"KC O\u2019Donnell","year":"2025","unstructured":"O\u2019Donnell KC, Grigsby J, Grob CS (2025) Healing, harms, and humility: expanding the scope of psychedelic-assisted psychotherapy research. Am J Psychiatry 182(1):13\u201316","journal-title":"Am J Psychiatry"},{"issue":"9","key":"6907_CR34","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison CL et al (2023) Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA 330(9):843\u2013853","journal-title":"JAMA"},{"issue":"1","key":"6907_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1176\/appi.ajp.20230664","volume":"181","author":"EE Schenberg","year":"2024","unstructured":"Schenberg EE et al (2024) Is poorly assisted psilocybin treatment an increasing risk? Am J Psychiatry 181(1):75\u201376","journal-title":"Am J Psychiatry"},{"key":"6907_CR36","unstructured":"Siegel DABAJS (2024) Psychedelic Psychiatry, in Reference Module in Neuroscience and Biobehavioral Psychology. Elsevier."},{"issue":"3","key":"6907_CR37","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.euroneuro.2013.12.006","volume":"24","author":"F Tyls","year":"2014","unstructured":"Tyls F, Palenicek T, Horacek J (2014) Psilocybin\u2013summary of knowledge and new perspectives. Eur Neuropsychopharmacol 24(3):342\u2013356","journal-title":"Eur Neuropsychopharmacol"},{"key":"6907_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101809","volume":"56","author":"R von Rotz","year":"2023","unstructured":"von Rotz R et al (2023) Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine 56:101809","journal-title":"EClinicalMedicine"},{"issue":"6","key":"6907_CR39","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2024.768","volume":"10","author":"M Wahba","year":"2024","unstructured":"Wahba M et al (2024) Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: case report and thematic analysis of one participant\u2019s experience. BJPsych Open 10(6):e229","journal-title":"BJPsych Open"},{"key":"6907_CR40","unstructured":"WATCH LIVE: FDA advisory panel reviews MDMA-drug 'ecstasy' to treat PTSD. Available from: https:\/\/www.youtube.com\/watch?v=EjzhsL1fRG0"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06907-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-025-06907-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06907-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T09:05:11Z","timestamp":1785747911000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-025-06907-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["6907"],"URL":"https:\/\/doi.org\/10.1007\/s00213-025-06907-7","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Washington University in St. Louis Institutional Review Board.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D.B.: No financial conflicts of interest to reportS.N.: Employee at the Johns Hopkins Center for Psychedelic and Consciousness Research,\u00a0which is funded by philanthropic support from the Steven and Alexandra Cohen Foundation, as. well as Tim Ferriss, Matt Mullenweg, Blake Mycoskie, and\u00a0Craig Nerenberg. The funders had no input on the design, execution, or interpretation of this reportJ.S.: Former employee of Sumitomo Pharma America, consulting fees from Longitude\u00a0Capital\/Silo Wellness\/Forbes & Manhattan, speakers fee from SunCloud HealthD.H. Grant funding (to Research Foundation for Mental Hygiene, NY State): Compass\u00a0Pathways, Relmada, Marinus, Intracellular Therapies, Beckley Scientific, NIAMS (M Walker,\u00a0PI), Velocity Foundation (Columbia; J Markowitz, PI). Scientific advisory board: Reset\u00a0Pharmaceuticals, Mind Medicine Inc. Honoraria: Johns Hopkins University Press, Columbia\u00a0University PressB.E. Co-Investigator on current Compass Pathways clinical trial, no current or prior financial\u00a0compensation for this roleE.L. Patent pending for sigma 1 agonists for COVID-19. Consulting: Merck, IngenioRx, PritilinICR, Boehringer-Ingelheim","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}